[go: up one dir, main page]

WO2016185509A1 - Composition de ginsénoside - Google Patents

Composition de ginsénoside Download PDF

Info

Publication number
WO2016185509A1
WO2016185509A1 PCT/JP2015/063977 JP2015063977W WO2016185509A1 WO 2016185509 A1 WO2016185509 A1 WO 2016185509A1 JP 2015063977 W JP2015063977 W JP 2015063977W WO 2016185509 A1 WO2016185509 A1 WO 2016185509A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginsenoside
composition
family
effect
fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2015/063977
Other languages
English (en)
Japanese (ja)
Inventor
金　昌樹
慶光 金
昌康 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KIM'S KOREAN GINSENG CO Ltd
Original Assignee
KIM'S KOREAN GINSENG CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KIM'S KOREAN GINSENG CO Ltd filed Critical KIM'S KOREAN GINSENG CO Ltd
Priority to PCT/JP2015/063977 priority Critical patent/WO2016185509A1/fr
Publication of WO2016185509A1 publication Critical patent/WO2016185509A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)

Definitions

  • Rb1, Rb2, Rc ⁇ Rd ⁇ Rg3 -3- The produced Rg3 is further changed into secondary decomposition products such as Rg5, Rz1, and Rk1 by heat treatment.
  • Rk1 is similar in structure to Rz1, but the position of the double bond in the “side chain” part that binds to the 5-membered ring of a polycyclic compound consisting of three 6-membered rings and one 5-membered ring is Is different.
  • Rg3 (S), Rg3 (R), Rg5, Rk1, and Rz1 are referred to as “Rg3 family” or “Rg3 family member”.
  • members of the Rg3 family produced by the degradation of major ginsenoside are minor ginsenosides and are easily absorbed when ingested.
  • Patent Document 1 JP 2006-502082 (Patent Document 1) describes a composition having a ratio of (Rg3 + Rg5) / (Rb1 + Rb2 + Rc + Rd) ”of 10 to 45.
  • Patent Document 2 JP-A-2004-519224 describes a composition in which the product contains Rh1, Rh2, CK, Rg2, Rg3, F2, Rg1, Rd, aglycone, and the like.
  • Patent Document 3 JP 2008-501791 (Patent Document 3) describes a composition for preventing or treating vascular stenosis and restenosis containing ginsenoside Rg3, Rg5 or Rk1 as an active ingredient.
  • Patent Document 4 JP-T-2008-502711 (Patent Document 4) discloses that carrot is acid-treated at a temperature of 50 to 80 ° C. and the treated carrot is steam-treated at a temperature of less than 110 ° C. for 0.5 to 15 hours. The processed carrot extract or its freeze-dried product is described. .
  • Patent Document 5 JP 2011-512404 (Patent Document 5) describes a composition in which at least one of a leaf extract and a processed product thereof contains at least one ginsenoside component of Rg3, Rg5 and Rk1 as an active ingredient. . -6- (Patent Document 6) JP-T-11-501322 (Patent Document 6) describes a ginseng or ginseng extract having a ratio of (Rg3 + Rg5) / (Rc + Rd + Rb1 + Rb2) of ginsenoside of 1.0 or more.
  • Patent Document 7 In JP-T-2007-520418 (Patent Document 7), vinegar having a pH of 2 to 4 is added to ginseng or a carrot extract and heated and extracted for 0.5 to 24 hours, and Rg3 is Rb1, Rb2, Rc, Rd, Re, Rf. , Rg1 and Rg3 are contained in an amount of 5 to 100%, and Rg3 + Rg5 + Rh1 is contained in an amount of 1 to 15%.
  • An object of the present invention is to provide an “Rg3 family composition” capable of exhibiting a medicinal effect that is more reliable and more excellent than before in order to meet such demands.
  • ginsenoside Rk2 as an essential component.
  • the composition of the present invention belongs to the category of “Rg3 family composition”.
  • Rg3 family composition For example, indefinite complaints such as fatigue, stiff shoulders, loss of appetite, insomnia, headache, cold limbs, and reduced energy
  • indefinite complaints such as fatigue, stiff shoulders, loss of appetite, insomnia, headache, cold limbs, and reduced energy
  • the Rg3 family composition is typically obtained by concentrating an extract extracted from ginseng by an alcohol extraction method, adjusting the pH with an acid, and then aging under a predetermined temperature condition for a predetermined time. It is obtained by collecting a precipitated portion of the powder and drying it into powder. Since the powder thus obtained is rich in Rg3 (S), Rg3 (R), Rk1, Rg5 and Rz1, these are referred to as “Rg3 family”. F3 and Rk2 that are target components are not detected. -2- In the search of patent documents including the above-mentioned patent documents 1 to 7, there is no hit even when searching using “F3” or “Rk2” as a keyword.
  • ginsenoside components are extracted by the methods described in Japanese Pharmacopoeia “Carrot” and “Koujin”. Further, after roughly purifying the ginsenoside component using a C18 column, it is filtered through a membrane filter to obtain a sample solution. Next, the target ginsenoside is separated and quantified by injecting the sample solution into high performance liquid chromatography (HPLC) using an octadecylsilylated silica gel packed column (C18 column).
  • HPLC high performance liquid chromatography
  • Example 1 The production methods of the 8 types of tablets shown in Table 1 described below are as follows ("parts" is parts by weight). First, an extract was extracted from red ginseng, but extracted at various temperatures and times with an extraction solvent having a different water / alcohol ratio to obtain various extract extracts. Next, the extract was heat-aged at various temperatures and times and pulverized by a spray drying method to obtain fine powders having different ginsenoside contents.
  • the 6 groups were distributed from the daily intake group to the 6 intake group.
  • the intake time was arbitrary during the day, and the intake was divided into multiple times. Ingested continuously for 1 month, all subjects checked subjective symptoms of stiff shoulders before and 1 month after ingestion. All subjects checked subjective symptoms for stiff shoulders before the start of the study and one month after ingestion. In the subjective symptom table, the situation for stiff shoulders is divided into seven stages as follows.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de ginsénoside dérivée du ginseng, et a pour objet de fournir une composition de la famille Rg3 qui développe de manière plus certaine des effets encore meilleurs que dans l'art antérieur. Plus précisément, l'invention concerne une composition qui comprend, en tant que composants de base, des composants appartenant à la famille Rg3 constituée de Ｒｇ３（Ｓ）, Ｒｇ３（Ｒ）, Ｒｋ１, Ｒｇ５ et Ｒｚ１. Cette composition de ginsénoside est caractéristique en ce qu'elle comprend un ginsénoside F3 en tant que composant essentiel (elle comprend également un ginsénoside RK2).
PCT/JP2015/063977 2015-05-15 2015-05-15 Composition de ginsénoside Ceased WO2016185509A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/063977 WO2016185509A1 (fr) 2015-05-15 2015-05-15 Composition de ginsénoside

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/063977 WO2016185509A1 (fr) 2015-05-15 2015-05-15 Composition de ginsénoside

Publications (1)

Publication Number Publication Date
WO2016185509A1 true WO2016185509A1 (fr) 2016-11-24

Family

ID=57319578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/063977 Ceased WO2016185509A1 (fr) 2015-05-15 2015-05-15 Composition de ginsénoside

Country Status (1)

Country Link
WO (1) WO2016185509A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441106A (zh) * 2017-09-11 2017-12-08 青海七彩花生物科技有限公司 一种人参皂苷rg5和rz1的药物组合物及在脑保护中的应用
CN107595865B (zh) * 2017-09-25 2018-08-14 徐州佳生医药科技有限公司 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用
CN117482124A (zh) * 2023-12-14 2024-02-02 延边安帝康华生物科技有限公司 一种药物组合物在制备血压双向调节的药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508877A (ja) * 2005-09-19 2009-03-05 ハーバルサイエンス シンガポール ピーティーイー． リミテッド パナックス種を含む組成物及び方法
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN102600189A (zh) * 2011-01-24 2012-07-25 吉林农业大学 人参次级皂苷及其脂肪酸酯衍生物在糖尿病中的应用
KR101330864B1 (ko) * 2013-04-02 2013-11-18 재단법인 금산국제인삼약초연구소 펙티나아제를 이용한 진세노사이드 Rd가 강화된 발효인삼 또는 발효홍삼의 제조방법
WO2014132430A1 (fr) * 2013-03-01 2014-09-04 金氏高麗人参株式会社 Composition de ginsenoside
WO2014176900A1 (fr) * 2013-04-28 2014-11-06 福建南方制药股份有限公司 Nano-micelle de saponines et procédé de préparation, utilisation et composition pharmaceutique associées

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508877A (ja) * 2005-09-19 2009-03-05 ハーバルサイエンス シンガポール ピーティーイー． リミテッド パナックス種を含む組成物及び方法
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN102600189A (zh) * 2011-01-24 2012-07-25 吉林农业大学 人参次级皂苷及其脂肪酸酯衍生物在糖尿病中的应用
WO2014132430A1 (fr) * 2013-03-01 2014-09-04 金氏高麗人参株式会社 Composition de ginsenoside
KR101330864B1 (ko) * 2013-04-02 2013-11-18 재단법인 금산국제인삼약초연구소 펙티나아제를 이용한 진세노사이드 Rd가 강화된 발효인삼 또는 발효홍삼의 제조방법
WO2014176900A1 (fr) * 2013-04-28 2014-11-06 福建南方制药股份有限公司 Nano-micelle de saponines et procédé de préparation, utilisation et composition pharmaceutique associées

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KI SUNG KANG ET AL.: "Stereospecificity in hydroxyl radical scavenging activities of four ginsenosides produced by heat processing", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 19, 2006, pages 5028 - 5031, XP027966579 *
NGUYEN, HUU TUNG ET AL.: "Dammarane-type saponins from the black ginseng", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 31, no. 11, 2010, pages 3423 - 3426, XP055330446 *
WANG YU KIM ET AL.: "Steaming of ginseng at high temperature enhances biological activity", JOURNAL OF NATURAL PRODUCTS, vol. 63, no. 12, 2000, pages 1702 - 1704, XP055228891 *
YU JUN-LI: "Immunoenhancing activity of protopanaxatriol-type ginsenoside-F3 in murine spleen cells", ACTA PHARMACOLOGICA SINICA, vol. 25, no. 12, 2004, pages 1671 - 1676, XP055330447, Retrieved from the Internet <URL:http://www.chinaphar.com/1671-4083/25/1671.htm> *
YUTAKA INAMOTO ET AL.: "Clinical use of red ginseng for postoperative cases, anemia and unidentified clinical syndrome", SHIN'YAKU TO RINSHO, vol. 34, no. 7, 1985, pages 164 - 177 *
ZHANG YING-CHUN ET AL.: "Tissue-specific distribution of ginsenosides in different aged ginseng and antioxidant activity of ginseng leaf", MOLECULES, vol. 19, 2014, pages 17381 - 17399, XP055330450 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441106A (zh) * 2017-09-11 2017-12-08 青海七彩花生物科技有限公司 一种人参皂苷rg5和rz1的药物组合物及在脑保护中的应用
CN107595865B (zh) * 2017-09-25 2018-08-14 徐州佳生医药科技有限公司 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用
CN117482124A (zh) * 2023-12-14 2024-02-02 延边安帝康华生物科技有限公司 一种药物组合物在制备血压双向调节的药物中的应用

Similar Documents

Publication Publication Date Title
Malík et al. Nootropics as cognitive enhancers: types, dosage and side effects of smart drugs
CN100450495C (zh) 加工人参的方法和加工过的人参提取物的用途
Yarnell et al. Clinical botanical medicine
JP2010124786A (ja) ショウガ加工食品組成物及びその製造方法
Obidoa et al. Phytochemical analysis of Cocos nucifera L
Yang Chinese ginseng
Zakynthinos et al. Hippophae rhamnoides: safety and nutrition
Gholamnezhad et al. The effect of chronic supplementation of Nigella sativa on splenocytes response in rats following treadmill exercise
WO2016185509A1 (fr) Composition de ginsénoside
EP2359839A2 (fr) Procédé de préparation d&#39;une fraction d&#39;extrait renforcée avec des ginsénosides rg1 ou rb1 issus du ginseng
CN108785370A (zh) 一种用于治疗高血脂症及动脉粥样硬化的药物组合物
JP2023519189A (ja) ギンセノシド組成物
CN106692145B (zh) 一种治疗血管性痴呆的药物
CN102579514A (zh) 一种八角枫的炮制方法
WO2000013696A1 (fr) Composition pour ameliorer les capacites mentales chez les mammiferes
Najah et al. Analytical and phytochemical studies on zizyphus lotus
CH712713B1 (de) Mit Maca angereicherter Kaffee und Verfahren zu seiner Herstellung.
KR102095621B1 (ko) 식품 첨가물의 제조방법
JP7514282B2 (ja) 肌くすみ抑制剤及び肌バリア機能維持又は改善剤
RU2636817C2 (ru) Средство, обладающее гиполипидемическим, гепатозащитным и антиоксидантным действием
Lei et al. A review of the ethnopharmacology, phytochemistry, and pharmacology of Changium smyrnioides Wolff
MX2010005839A (es) Composiciones farmaceuticas para tratar la ansiedad.
Skenderidis et al. Goji bery: Important bioactive ingredients. A mini-review
Al-Achi A concise treatise on natural remedies
CN102961418B (zh) 一种复方沙棘双嘧片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15892510

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15892510

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP